Constancy in integrated cisplatin plasma concentrations among pediatric patients

Journal of Clinical Pharmacology

Volumn 46, Issue 4, 2006, Pages 443-448

  Goodisman, Jerry ^a   Souid, Abdul Kader ^b  

^a SYRACUSE UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Carboplatin; Cisplatin; Drug modeling; Pharmacokinetics

Indexed keywords

CISPLATIN; IRINOTECAN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PARAMETER; POPULATION; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY HEIGHT; BODY SURFACE AREA; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; REPRODUCIBILITY OF RESULTS;

EID: 33644983584     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006286793     Document Type: Article

References (14)

1. Corden BJ, Fine RL, Ozols RF, Collins JM. Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol. 1985;14:38-41.
2. Desoize B, Dumont P, Manot L, Urien S, Dufour R, Bertoit G. Comparison of two dose prediction models for cisplatin. Anticancer Res. 1994;14:2285-2290.
3. El-Kareh AW, Secomb TW. A mathematical model for cisplatin pharmacodynamics. Neoplasia. 2003;5:161-169.
4. Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823-1828.
5. Vermorken JB, van der Vijgh WJ, Klein I, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Thepeut. 1986;39:136-144.
6. Souid A-K, Dubowy RL, Blaney SM, et al. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors: Children's Oncology Group trial 9970. Clin Cancer Res. 2003;9:703-710.
7. Thomas HD, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: a United Kingdom Children's Cancer Study Group Trial. J Clin Oncology. 2000;18:3614-3621.
8. Calvert AH, Egorin MJ. Carboplatin dosing formulas: gender bias and the use of creatinine-based methodologies. Eur J Cancer. 2002;38:11-16.
9. Madhu M, Smith A, Tong WP, Motzer RJ. Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting. J Nat Cancer Inst. 2000;92:1434-1436.
10. Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncology. 1993;11:2314-2323.
11. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in pediatric cancer patients. Eur J Cancer. 1995;31:1804-1810.
12. Welling PG. Pharmacokinetics: Processes and Mathematics. Washington DC: American Chemical Society; 1986.
13. Rescigno A. Fundamental concepts in pharmacokinetics. Pharmacol Res. 1997;35:363-390.
14. de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol. 2004;54:105-112.